Improving existing treatment and therapy options by utilizing expertise in the pharmacology of anti-TB drugs; through the use of pharmacokinetic/pharmacodynamic (PK/PD) analysis to optimize treatment regimens; and the exploration of safety and PK in people living with HIV, children and pregnant women.

Active Projects

  • Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium (UM1); PIs - Rada Savic (UCSF) Kelly Dooley (VUMC); NIH UM1AI179699
  • Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS) (R01); PI - Jeffery Tornheim (Johns Hopkins) Kelly Dooley (VUMC); NIH R01AI168371

Completed Projects

  • Investigating Multiple PK and PD Relationships for TB-HIV (IMPPRove TB-HIV) (R56); PI - Kelly Dooley; NIH R56AI174911
  • Innovative PK/PD approaches to optimize TBM treatment in children (TBM-KIDS trial); Baltimore, MD; PI - Kelly Dooley; NIH R01HD074944
  • Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis IND 117472; Baltimore, MD; PI - Kelly Dooley; FDA R01FD004794
  • Ph2a Study: Rifampin, Meropenem, Augmentin for Tuberculosis (COMRADE trial) IND 129159; Baltimore, MD; PI - Kelly Dooley; FDA R01FD005724
  • ACTG Study A5409, "A Phase 2A+ Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB)"
  • Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa; South Africa; PIs - Naidoo, Anushka, Kelly Dooley; NIH R01AI152142